Needham Downgrades Esperion Therapeutics to Hold From Buy
Esperion Therapeutics (ESPR) has an average rating of Hold and mean price target of $3.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)